TNGX Tango Therapeutics, Inc. Loading...

Loading chart...
Top Calls
Feed
Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
01:44
Jun 13
seedy19tron Biotech trader, L/S
The author maps out M&A scenarios in oncology but presents them as possibilities and research, not current positions or explicit trade calls.
TNGX
LOW
23:23
Jun 12
seedy19tron Biotech trader, L/S
Buy TNGX as both the data catalyst (pan-RAS(ON) + PRMT5 combination validation) and a potential acquisition target; author sees MRK as a possible acquirer of TNGX paired with ERAS in back-to-back deals.
TNGX 1ST
MED
14:52
Jun 08
Bloomberg Newswire (@business)
Tango shares surged as much as 48% after early study results showed its drug combined with a Revolution Medicine treatment shrank tumors in advanced pancreatic cancer patients.
TNGX

About TNGX Analyst Coverage

Buzzberg tracks TNGX (Tango Therapeutics, Inc.) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (33%). 3 total trade ideas tracked. Past 7 days: 1 bullish, 2 watch. Latest voices: seedy19tron, Bloomberg.